Obesity Management Efforts in the Workplace; Use of Glucagon-Like Peptide-1 (GLP-1) Medication

Obesity is the most significant contributor to the burden of chronic diseases in the U.S., accounting for 47% of the total cost of chronic diseases nationwide. It currently affects more than 31% of full-time employees, and another 37% of the workforce is overweight. Insurers, health plans, and self-funded employers are grappling with how to cover the use of GLP-1. This session covered plan designs, the risks and comorbidities of obesity and the use of GLP-1 medications, weight loss surgery, how GLP-1 drugs work, and the impact of GLP-1 medication on the cost of healthcare.

Speakers

• Celine Cannizzaro, Head of Pharmacy & Healthcare Strategy, Berkshire Hathaway Inc.
• Christan Royer, Sr. Director at Indiana University
• Jennifer Dimura, Executive Vice President, Pharmacy Practice, Alliant Insurance
• Laura Dalferes, Director of Benefits at Franciscan Missionaries of Our Lady Health System
• Joel Silverberg, MD, Endocrinologist at Baton Rouge Clinic
• Mark Haussman, MD, Bariatric Surgeon, Surgeons Group of Baton Rouge, Inc.
• Chet Pilley, Director of Analytics at Cadence Insurance
• Mike Bertaut, Healthcare Economist, BCBSLA

 

Presentations

Alliant Pharmacy Practice Slides
Presented to Jennifer Dimura is the Executive Vice President, National Director of Pharmacy at Alliant Insurance Services.

View Presentation

GLP-1s & Obesity
Presented by: Chet Pilley, Director of Analytics at Cadence Insurance

View Presentation